These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2959202)

  • 21. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
    Osborne CK; Hobbs K; Clark GM
    Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-steroid hormones for uterine cancer].
    Komiyama S; Nishio E; Yasue A; Hasegawa K; Udagawa Y
    Nihon Rinsho; 2008 Jan; 66(1):174-81. PubMed ID: 18186261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Endocrine therapy of breast cancer].
    Jonat W; Maass H
    Zentralbl Gynakol; 1987; 109(10):617-27. PubMed ID: 2956805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
    Kawai K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroid receptors in prostate cancer tissues and cells: pathophysiology, problems in methodology, clinical value and controversial questions.
    Pavone-Macaluso M; Carruba G; Castagnetta L
    Arch Esp Urol; 1994 Mar; 47(2):189-201. PubMed ID: 8002681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Developments in endocrine therapy for breast cancer].
    Matsui A; Ikeda T; Jinno H; Tajima G; Hohjou T; Tokura H; Mitsui Y; Asaga S; Muto T; Kitajima M
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1138-45. PubMed ID: 12145993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.
    Benz C; Hollander C; Miller B
    Cancer Res; 1986 May; 46(5):2276-81. PubMed ID: 3697973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hormonal therapy in endometrial cancer].
    Kanoh H; Okudaira Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2306-10. PubMed ID: 8259843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
    Lorenz I; Mechl Z
    Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cancer of the prostate: new hormone therapies].
    Namer M; Boublil JL; Kather R; Cavaglione G
    Bull Cancer; 1986; 73(1):47-55. PubMed ID: 3779122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LH-RH-endocrine manipulation in cancer of the prostate.
    Falcone T; Falutz G; Tolis G
    Biomed Pharmacother; 1982; 36(8-9):344-8. PubMed ID: 6303470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
    Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth inhibitory effect of LH-RH analogs on human breast cancer cells.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Gaggini C; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(1):187-90. PubMed ID: 2965864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.